DOCSLIB.ORG

(2) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(2) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub US 20160354315A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub. Date: Dec. 8, 2016 (54) DOSAGE FORMS AND USE THEREOF Publication Classification (71) Applicant: Triastek, Inc., Nanjing (CN) (51) Int. Cl. A61 K 9/20 (2006.01) (72) Inventor: Xiaoling Li, Dublin, CA (US) A61 K 9/24 (2006.01) A61 K 31/192 (2006.01) (52) U.S. CI. (21) Appl. No.: 15/173,596 CPC ........... A61K 9/2031 (2013.01); A61K 9/2027 (2013.01); A61K 31/192 (2013.01); A61 K 9/209 (2013.01) (22) Filed: Jun. 3, 2016 (57) ABSTRACT The present disclosure provides a stable solid pharmaceuti Related U.S. Application Data cal dosage form for oral administration. The dosage form - - - ... - includes a substrate that forms at least one compartment and (60) Provisional application No. 62/170,645, filed on Jun. a drug content loaded into the compartment. The dosage 3, 2015, provisional application No. 62/313,092, filed form is so designed that the active pharmaceutical ingredient on Mar 24, 2016. of the drug content is released in a controlled manner. Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 A1 FIG. HA : FIG. B ; Peak concentration, Cuax fiase FIG. 1 C Patent Application Publication Dec. 8, 2016 Sheet 2 of 20 US 2016/0354315 A1 | : FIG. 2B Patent Application Publication Dec. 8, 2016 Sheet 3 of 20 US 2016/0354315 A1 202 FIG. 3 Patent Application Publication Dec. 8, 2016 Sheet 4 of 20 US 2016/0354315 A1 Patent Application Publication Dec. 8, 2016 Sheet 5 of 20 US 2016/0354315 A1 FIG. 4E FIG. 5 Patent Application Publication Dec. 8, 2016 Sheet 6 of 20 US 2016/0354315 A1 Patent Application Publication Dec. 8, 2016 Sheet 7 of 20 US 2016/0354315 A1 : FIG. 8B Patent Application Publication Dec. 8, 2016 Sheet 8 of 20 US 2016/0354315 A1 FIG. 9 Patent Application Publication Dec. 8, 2016 Sheet 9 of 20 US 2016/0354315 A1 FIG. 10B Patent Application Publication Dec. 8, 2016 Sheet 10 of 20 US 2016/0354315 A1 : t3 FIG. 10C FIG. 10D Patent Application Publication Dec. 8, 2016 Sheet 11 of 20 US 2016/0354315 A1 Prescription ----------------------------- #ith specific dose and ~ * & drug costbination & sº “A; \" /* ºf* FIG. 11 Patent Application Publication Dec. 8, 2016 Sheet 12 of 20 US 2016/0354315 A1 FIG. 12A FIG. 12B Patent Application Publication Dec. 8, 2016 Sheet 13 of 20 US 2016/0354315 A1 FIG. 13A FIG. 13B Patent Application Publication Dec. 8, 2016 Sheet 14 of 20 US 2016/0354315 A1 : FIG. 14C Patent Application Publication Dec. 8, 2016 Sheet 15 of 20 US 2016/0354315 A1 FIG. 15A : FIG. 15B Patent Application Publication Dec. 8, 2016 Sheet 16 of 20 US 2016/0354315 A1 4300 2’ 1 3 0. 3 …” …” ~~*~~~ - 1304 ( cº, cº, cº) ~ | | | | | |_- 1301 %. --- -- -----. 4. *... : FIG. 16B Patent Application Publication Dec. 8, 2016 Sheet 17 of 20 US 2016/0354315 A1 1401 1404 FIG. 17A : FIG. 17B FIG. 17C Patent Application Publication Dec. 8, 2016 Sheet 19 of 20 US 2016/0354315 A1 FIG. 19A FIG. 19B Patent Application Publication Dec. 8, 2016 Sheet 20 of 20 US 2016/0354315 A1 0.30 0.25 0.20 0.15 0, 10 0.05 0.00 0 20 40 60 80 400 420 Time (min) FIG. 19C 0.48 0.46 0.44 0.42 0.40 # 0.08 0.06 0.04 0.02 0.00 –0.02 O 20 40 60 80 100 Time (min) FIG. 190 US 2016/0354315 A1 Dec. 8, 2016 DOSAGE FORMS AND USE THEREOF copolymer 57/30/13, polyvinylpyrrolidone-co-vinyl-acetate (PVP-VA), polyvinylpyrrolidone-polyvinyl acetate copoly CROSS-REFERENCE TO RELATED mer (PVP-VA) 60/40, polyvinylpyrrolidone (PVP), polyvi APPLICATIONS nyl acetate (PVAc) and polyvinylpyrrolidone (PVP) 80/20, polyethylene glycol-polyvinyl alcohol graft copolymer [0001] This application claims priority to U.S. Provisional 25/75, kollicoat IR-polyvinyl alcohol 60/40, polyvinyl alco Patent Applications Ser. Nos. 62/170,645, filed Jun. 3, 2015, hol (PVA or PV-OH), poly(vinyl acetate) (PVAc), poly(butyl 62/296,087, filed Feb. 17, 2016 and 62/313,092, filed Mar. methacrylate-co-(2-dimethylaminoethyl) methacrylate-co 24, 2016, the entire disclosures of which are incorporated methyl methacrylate) 1:2:1, poly(dimethylaminoethylmeth herein by reference. acrylate-co-methacrylic esters), poly(ethyl acrylate-co FIELD OF THE INVENTION methyl methacrylate-co-trimethylammonioethyl methacrylate chloride), poly(methyl acrylate-co-methyl [0002] The present invention generally relates to a phar methacrylate-co-methacrylic acid) 7:3:1, poly(methacrylic maceutical dosage form and controlled release of biologi acid-co-methylmethacrylate) 1:2, poly(methacylic acid-co cally active agents, diagnostic agents, reagents, cosmetic ethyl acrylate) 1:1, poly(methacylic acid-co-methyl meth agents, and agricultural/insecticide agents. acrylate) 1:1, poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), hyperbranched polyesteramide, hydroxypro BACKGROUND pyl methylcellulose phthalate, hypromellose phthalate, [0003) Pharmaceutical drug products must be manufac hydroxypropyl methylcellulose or hypromellose (HMPC), tured into dosage forms in order to be marketed for use. hydroxypropyl methylcellulose acetate succinate or Conventional dosage forms typically involve a mixture of hypromellose acetate succinate (HPMCAS), poly(lactide active pharmaceutical ingredients and inactive components co-glycolide) (PLGA), carbomer, poly(ethylene-co-vinyl (excipients), along with other non-reusable materials such as acetate), ethylene-vinyl acetate copolymer, polyethylene a capsule shell. Categories of dosage forms include liquid (PE), and polycaprolactone (PCL), hydroxyl propyl cellu dosage forms (e.g., solutions, syrups, elixirs, suspensions lose (HPC), Polyoxyl 40 Hydrogenerated Castor Oil, Methyl and emulsions), solid dosage forms (e.g., tablets, capsules, cellulose (MC), Ethyl cellulose (EC), Poloxamer, hydroxy caplets and gel-caps), and semi-solid dosage form (e.g., propyl methylcellulose phthalate (HPMCP), Poloxamer, ointments and suppositories), among which solid dosage Hydrogenated Castor & Soybean Oil, Glyceryl Palmitoste forms are more advantages to administer drugs in systemic arate, Carnauba Wax, polylactic acid (PLA), polyglycolic effect through oral route. acid (PGA), Cellulose acetate butyrate (CAB), Colloidal [0004] Tablets are most commonly used solid dosage Silicon, Dioxide, Sucrose, Glucose, Polyvinyl Acetate forms, which shows more benefits in terms of manufactur Phthalate (PVAP) and a combination thereof. ing, packaging and shipping, and easy to identify and [0007] In certain embodiments, the compartment has a swallow. After being administered into a living organism, a shape selected from the group consisting of a pie shape, a tablet undergoes interplay with the body in exerting phar cone shape, a pyramid shape, a cylindrical shape, a cubic or maceutical effects. The active pharmaceutical ingredient cuboidal shape, a triangular or polygonal prism shape, a must be released from the tablet before being absorbed into tetrahedron and a combination thereof. the blood circulation. The pharmaceutical ingredient then [0008] In certain embodiments, the first drug content is in disperses, disintegrates or dissolves throughout the fluids a form of nanoparticles, microneedles or forms a net. and tissues of the body. During drug absorption, disposition, [0009] In certain embodiments, the drug content com metabolism, and elimination process, dosage forms play a prises an active pharmaceutical ingredient (API). In certain critical role in determining the release profile and bioavail embodiments, the API is selected from the groups consisting ability of the drugs. Therefore, there is a continuing needs of local anesthetics, antiepileptic drugs and anticonvulsants, for developing dosage forms that provides controlled drug anti-Alzheimer’s disease drugs, analgesics, antipodagric, delivery systems, which may offer desired drug plasma anti-hypertensive drugs, antiarrhythmic drugs, diuretic levels, reduced side effects as well as improved patient drugs, drugs for treating liver diseases, drugs for treating compliance. pancreatic diseases, antihistamine drugs, anti-allergic drugs, glucocorticoid drugs, hormone drugs and contraceptive BRIEF SUMMARY OF THE INVENTION drugs, hypoglycemic drugs, anti-osteoporosis drugs, antibi [0005] In one aspect, the present disclosure provides a otics, sulfonamides, quinolones, and other synthetic antibac dosage form including a substrate forming at least one terial drugs, anti-tuberculosis drugs, antiviral drugs, anti compartment and a drug content loaded into the compart neoplasm drugs, immune-modulators, cosmetically active ment. In certain embodiments, the drug content is operably agents and traditional Chinese medicine. In certain embodi linked to the substrate. In certain embodiments, the drug ments, the API is a biologically active agent, a diagnostic content is detached from the substrate and freely movable in agent, a reagent for scientific research, a cosmetic agent, or the compartment. an agricultural/insecticide agent. [0006] In certain embodiments, the substrate is made from [0010] In certain embodiments, the drug content further a thermoplastic material selected from the group consisting comprises an excipient. In certain embodiments, the excipi of a hydrophilic polymer, a hydrophobic polymer, a ent is made from materials selected from the group consist swellable polymer, a non-swellable polymer, a porous poly ing of cocoa butter, polyethylene glycol (PEG), sucrose, mer, a non-porous polymer, an erodible polymer, a non glucose, galactose, fructose, xyloselactose, maltose, treha erodible polymer. In certain embodiments, the thermoplastic lose, sorbitol,
Load more

Recommended publications
  • Dipiperon®) Is a Mild to Moderately Potent Butyrophenone Neuroleptic and Is Used in the Treatment of Psychosis and Severe Agitation
    Pipamperone and increased appetite/weight Introduction Pipamperone (Dipiperon®) is a mild to moderately potent butyrophenone neuroleptic and is used in the treatment of psychosis and severe agitation. It is a 5-HT(2) receptor antagonist and demonstrates weak affinity for alpha1-adrenergic and D2-receptors. Pipamperone has not been associated with anticholinergic effects. Pipamperone has been approved for the Dutch market since 1968[1]. Weight gain is a well-known side-effect of antipsychotics, alone or part of a metabolic syndrome. Weight gain, diabetes, dyslipidemia, diabetic ketoacidosis, and cardiovascular disease constitute a metabolic syndrome usually associated with second-generation antipsychotics, presenting with comparable frequency in first-generation antipsychotics. The mechanism by which these symptoms are produced is not entirely clear. There is some evidence for both increased appetite and altered metabolic control with these drugs. Patient-related factors include pre-existing metabolic issues. Those who are obese, diabetic or prediabetic, or have high-risk lipid profiles are more likely to experience problems with these medications than other patients. Increased susceptibility for metabolic side effects in patients with some of the disorders they are treated for, particularly schizophrenia, may also play a role [2]. Reports Between April 1989 and April 2017 Lareb received 12 reports of weight increased and/or increased appetite associated with the use of pipamperone. Table 1. Cases of pipamperone and increased weight/appetite
    [Show full text]
  • Crofelemer Oral Delayed Release Tablet
    Contains Nonbinding Recommendations Draft – Not for Implementation Draft Guidance on Crofelemer This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Crofelemer Dosage Form; Route: Tablet, delayed release; oral Strength: 125 mg Recommendations for the Assessment of Identity and Quality of Botanical Raw Material (BRM): Crofelemer is a botanical drug derived from BRM, the crude red latex of Croton lechleri Müll. Arg. [Fam. Euphorbiacae], which is also called dragon’s blood (sangre de drago). Generic drug applicants should use the same plant species and perform BRM assessment: 1. Crofelemer BRM should be collected from the crude red latex of Croton lechleri. The plant species should be correctly identified and authenticated based on techniques such as macroscopic/microscopic and/or analysis of genetic material. 2. Crude red latex as BRM should be collected from the mature tree with defined eco- geographic regions (EGRs). Implementing and enforcing established good agricultural and collection practice (GACP) procedures will minimize variations in BRM and ensure batch- to-batch consistency of crofelemer. 3. BRMs should be analyzed for their crofelemer content, total phenolics and taspine content, as well as heavy metals and pesticides. Recommendations for Demonstrating API Sameness: API sameness can be established by showing equivalence between Test API and API from the reference listed drug (RLD) product with the three criteria described in detail below.
    [Show full text]
  • Mrna Expression of SMPD1 Encoding Acid Sphingomyelinase Decreases Upon Antidepressant Treatment
    International Journal of Molecular Sciences Article mRNA Expression of SMPD1 Encoding Acid Sphingomyelinase Decreases upon Antidepressant Treatment Cosima Rhein 1,2,* , Iulia Zoicas 1 , Lena M. Marx 1, Stefanie Zeitler 1, Tobias Hepp 2,3, Claudia von Zimmermann 1, Christiane Mühle 1 , Tanja Richter-Schmidinger 1, Bernd Lenz 1,4 , Yesim Erim 2, Martin Reichel 1,† , Erich Gulbins 5 and Johannes Kornhuber 1 1 Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, D-91054 Erlangen, Germany; [email protected] (I.Z.); [email protected] (L.M.M.); [email protected] (S.Z.); [email protected] (C.v.Z.); [email protected] (C.M.); [email protected] (T.R.-S.); [email protected] (B.L.); [email protected] (M.R.); [email protected] (J.K.) 2 Department of Psychosomatic Medicine and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany; [email protected] (T.H.); [email protected] (Y.E.) 3 Institute of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany 4 Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, D-68159 Mannheim, Germany 5 Department of Molecular Biology, University Hospital, University of Duisburg-Essen, D-45147 Essen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-9131-85-44542 Citation: Rhein, C.; Zoicas, I.; Marx, † Current address: Department of Nephrology and Medical Intensive Care, Charité—Universitätsmedizin L.M.; Zeitler, S.; Hepp, T.; von Berlin, Berlin, Germany.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • CTRI Trial Data
    PDF of Trial CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Wed, 29 Sep 2021 01:52:07 GMT) CTRI Number CTRI/2013/09/003944 [Registered on: 02/09/2013] - Trial Registered Retrospectively Last Modified On 26/07/2013 Post Graduate Thesis Yes Type of Trial Interventional Type of Study Drug Study Design Randomized, Parallel Group, Multiple Arm Trial Public Title of Study A comparative study to evaluate the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients of Acid peptic disorders. Scientific Title of A prospective, comparative, controlled, randomized, open label, parallel, 3-arm study to evaluate Study and compare the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients suffering from acid peptic disorders Secondary IDs if Any Secondary ID Identifier NIL NIL Details of Principal Details of Principal Investigator Investigator or overall Name Dr Sagar Katare Trial Coordinator (multi-center study) Designation Junior Resident Affiliation Government Medical College, Aurangabad Address Department of Pharmacology, 3rd floor, College building, Government Medical College and Hospital (GHATI), Panchakki road, Navkheda Aurangabad MAHARASHTRA 431001 India Phone 9029015821 Fax Email [email protected] Details Contact Details Contact Person (Scientific Query) Person (Scientific Name Dr Kantilal Chandaliya Query) Designation Associate Professor Affiliation Government Medical College, Aurangabad Address Department of Pharmacology,
    [Show full text]
  • Research Article the Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries
    Hindawi Gastroenterology Research and Practice Volume 2019, Article ID 6532876, 7 pages https://doi.org/10.1155/2019/6532876 Research Article The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries Jing Zhao ,1,2 Yihong Fan ,1,2 Wu Ye ,1 Wen Feng ,1 Yue Hu ,1,2 Lijun Cai ,1,2 and Bin Lu 1,2 1Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, China 2Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China Correspondence should be addressed to Bin Lu; [email protected] Received 16 July 2018; Accepted 28 November 2018; Published 18 June 2019 Academic Editor: Haruhiko Sugimura Copyright © 2019 Jing Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Aspirin usage is associated with increased risk of gastrointestinal bleeding. The present study explored the potential of teprenone, an antiulcerative, in preventing aspirin-related gastric mucosal injuries. Methods. 280 patients with coronary diseases, naïve to aspirin medication, were admitted between 2011 and 2013 at the First Affiliated Hospital of Zhejiang Chinese Medical University and randomized into two groups (n = 140). The aspirin group received aspirin enteric-coated tablets 100 mg/day, while the aspirin+teprenone group received teprenone 50 mg 3 times/day along with aspirin. The patients were recorded for gastrointestinal symptoms and gastric mucosal injuries during a follow-up period of 12 months with 3-month intervals.
    [Show full text]
  • A Long Term Clinical Diagnostic-Therapeutic
    Psychiatria Danubina, 2013; Vol. 25, Suppl. 2, pp 190–193 Conference paper © Medicinska naklada - Zagreb, Croatia A LONG TERM CLINICAL DIAGNOSTIC-THERAPEUTIC EVALUATION OF 30 CASE REPORTS OF BIPOLAR SPECTRUM MIXED STATES Giuseppe Tavormina "Psychiatric Studies Center" (Cen.Stu.Psi.), Provaglio d'Iseo (BS), Italy SUMMARY The aim of this study is to show how managing long term patients who are diagnosed as having bipolar disorder with an affective mixed states can cause them to achieve a high level of recovery from the illness and quality of life. This study observed all consecutive new patients who were seen in a private psychiatry practice during the years 2008-2009- 2010 who had a diagnosis within the mixed states sub-group (Irritable Cyclothymia, Mixed Disphoria and Agitated Depression)Thirty patients were selected who presented with a score of less than 40 on the Global Assessment Scale (GAS). They were reassessed by readministering the GAS scale after six months and after two years treatment. The final results demonstrate an improvement of the mood of the patients and their increasing quality of life.Almost all reached a value on the GAS scale of between 60 and 80 after six months, and between 90 and 100 scores after two years. Key words: bipolar spectrum disorders – mixed states – long time treatment * * * * * BACKGROUND and in Agitated Depression. The main symptoms present are the following: The aim of this study is to show how to manage long overlapping depressed mood and irritability; time patients with serious mixed states bipolar disorders high internal and muscular tension; by describing 30 cases reports, and demonstrating that reduced ability to concentrate and mental over- they can achieve a high level of recovery from the activity; illness and improvement in the quality of life.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate
    21822182 Infrared Reference Spectra JP XVII Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21832183 Quinapril Hydrochloride Quinine Ethyl Carbonate Quinine Sulfate Hydrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21842184 Infrared Reference Spectra JP XVII Rabeprazole Sodium Ranitidine Hydrochloride Rebamipide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21852185 Reserpine Ribavirin Rifampicin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21862186 Infrared Reference Spectra JP XVII Risperidone Ritodrine Hydrochloride Rokitamycin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • The Toronto Consensus for the Treatment of Helicobacter Pylori Infection in Adults Carlo A
    Gastroenterology 2016;151:51–69 CONSENSUS STATEMENT The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults Carlo A. Fallone,1 Naoki Chiba,2,3 Sander Veldhuyzen van Zanten,4 Lori Fischbach,5 Javier P. Gisbert,6 Richard H. Hunt,3,7 Nicola L. Jones,8 Craig Render,9 Grigorios I. Leontiadis,3,7 Paul Moayyedi,3,7 and John K. Marshall3,7 1Division of Gastroenterology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; 2Guelph GI and Surgery Clinic, Guelph, Ontario, Canada; 3Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada; 4Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 5Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas; 6Gastroenterology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; 7Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada; 8Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, Departments of Paediatrics and Physiology, University of Toronto, Toronto, Ontario, Canada; and 9Kelowna General Hospital, Kelowna, British Columbia, Canada This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e25. Learning Objective: Upon completion of this examination, successful learners will be able to establish a treatment plan for patients with H pylori infection. BACKGROUND & AIMS: Helicobacter pylori infection is lthough the prevalence of H pylori is decreasing in increasingly difficult to treat. The purpose of these consensus A some parts of the world, the infection remains pre- statements is to provide a review of the literature and specific, sent in 28% to 84% of subjects depending on the population updated recommendations for eradication therapy in adults.
    [Show full text]
  • Aggravation by Paroxetine, a Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-Inflammatory Drugs in Rats
    JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 JPET ThisFast article Forward. has not been Published copyedited andon formatted.June 24, The 2011 final versionas DOI:10.1124/jpet.111.183293 may differ from this version. JPET #183293 . Aggravation by Paroxetine, A Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-inflammatory Drugs in Rats Downloaded from Koji Takeuchi, Akiko Tanaka, Kazuo Nukui, Azusa Kojo, Melinda Gyenge, and Kikuko Amagase jpet.aspetjournals.org at ASPET Journals on September 25, 2021 Division of Pathological Sciences Department of Pharmacology and Experimental Therapeutics Kyoto Pharmaceutical University Misasagi, Yamashina, Kyoto 607-8414, Japan (K.T., A.T., K.N., A.K., M.G., K.A.) 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 This article has not been copyedited and formatted. The final version may differ from this version. JPET #183293 . Short title: Aggravation by SSRIs of NSAID-Induced Antral Damage Address correspondence to: Dr. Koji Takeuchi Division of Pathological Sciences Department of Pharmacology and Experimental therapeutics Kyoto Pharmaceutical University Downloaded from Misasagi, Yamashina, Kyoto 607-8414, Japan Tel: (Japan) 075-595-4679; Fax: (Japan) 075-595-4774 E-mail: [email protected] jpet.aspetjournals.org Document statistics: text ------------------------ 21 pages (page 4~page 25) at ASPET Journals on September 25, 2021 figures ----------------------- 10 figures references ----------------------- 43 references (page 27~page 31) Number of words: abstract ----------------------- 247 introduction ----------------------- 410 discussion -----------------------1685 Recommended section: Gastrointestinal, Hepatic, Pulmonary, & Renal 2 JPET Fast Forward.
    [Show full text]